Masimo Corporation (MASI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a mixed picture: strong EPS growth and improved margins were overshadowed by unchanged revenue guidance and tariff impacts. Positive feedback on sales restructuring and strong partnerships were tempered by management's vague responses on future initiatives. The Q&A highlighted uncertainties about the timing of new products and sales impacts. The stock price is likely to remain stable due to these mixed signals, with no clear catalyst for significant movement in either direction.
Key Financial Performance
Revenue $370 million, up 7.4% year-over-year on a constant currency basis. The increase was driven by 8.4% growth in consumables and service revenue, partially offset by a 2% decline in capital equipment and other revenue due to a transition from capital lease to operating lease accounting under ASC 42.
Earnings Per Share (EPS) $1.33, representing 46% growth year-over-year. The growth was attributed to improved operating margins and a lower tax rate due to greater profits from outside the U.S.
Gross Margin 62.9%, improved by 40 basis points year-over-year. This was driven by 90 basis points of operational improvement, partially offset by 50 basis points of tariff impact.
Operating Margin 27.5%, improved by 600 basis points year-over-year. This improvement was driven by 650 basis points of operational improvement, partially offset by 50 basis points of tariff impact.
Operating Cash Flow $62 million, which allowed the company to repay $38 million in debt and repurchase $14 million worth of common stock.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Intelligent Monitoring: Masimo is upgrading its centers and creating next-gen monitors featuring advanced AI-based algorithms. These innovations include the ability to detect cardiac dysfunction, such as atrial fibrillation, using just a pulse oximetry sensor.
Wearable Technologies: Masimo is piloting wearable technology and telemonitoring solutions to address unmet patient needs and expand long-term growth potential.
Market Expansion in Advanced Monitoring: Masimo is leveraging its leadership in pulse oximetry to expand into adjacent markets like capnography, brain monitoring, hemodynamics, and automation, which collectively represent markets worth $1-2 billion and are growing at high single digits. The company aims for 10%-20% growth in these areas.
Cost Structure Optimization: Masimo achieved 600 basis points of operating margin expansion due to effective cost structure actions taken last year.
Tariff Mitigation: The company reduced its tariff burden by over 50% through supply chain adjustments and administrative efforts, contributing to improved financial guidance.
Leadership Restructuring: Masimo added several key leadership roles, including Chief Commercial Officer, President of Japan and Asia Pacific, Chief Marketing and Strategy Officer, and others, to drive growth and innovation.
Divestiture of Sound United: The divestiture of Sound United is on track to close by the end of the year, with proceeds expected to be used for share repurchases, debt reduction, and acquisitions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Event: The company faced a cybersecurity event that incurred net expenses of approximately $4.5 million to recover and fortify systems. This event highlights vulnerabilities in IT infrastructure and potential risks to operations and data security.
Tariff Impact: New tariffs have increased costs, with products manufactured in Mexico, Malaysia, and China being affected. Although mitigation efforts have reduced the tariff burden by over 50%, tariffs still represent a significant cost challenge, impacting operating margins and financial performance.
Supply Chain Adjustments: Adjustments to the supply chain to mitigate tariff impacts involve administrative and operational efforts, which could strain resources and delay other strategic initiatives.
Capital Equipment Revenue Decline: Capital equipment and other revenue declined by 2%, partly due to a transition from capital lease to operating lease accounting. This shift created a headwind to total revenue growth.
Regulatory Clearance for Divestiture: The divestiture of Sound United is subject to obtaining necessary regulatory clearances, which could delay the transaction and impact the company's financial strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: Masimo projects revenue for fiscal 2025 to be in the range of $1.505 billion to $1.535 billion, reflecting 8% to 11% growth on a constant currency basis.
Earnings Per Share (EPS) Guidance: The company updated its EPS guidance to a range of $5.20 to $5.45, representing an increase of $0.35 at the midpoint versus prior guidance. This reflects year-over-year growth of 24% to 30%.
Operating Margins: Excluding the impact of new tariffs, operating margins are projected to be in the range of 28.3% to 28.7%, reflecting a year-over-year improvement of 460 to 500 basis points. Including tariffs, operating margins are expected to be in the range of 27% to 27.5%, representing an increase of 130 basis points at the midpoint versus prior guidance.
Tariff Impact Mitigation: Masimo has reduced its projected tariff impact by more than 50% compared to prior estimates, with further medium-term mitigation measures identified to reduce the burden over time.
Growth in Adjacent Markets: The company aims to achieve 10% to 20% growth in adjacent markets such as capnography, brain monitoring, hemodynamics, and automation, leveraging its leadership in pulse oximetry.
Intelligent Monitoring: Masimo plans to upgrade its centers and create next-generation monitors featuring advanced AI-based algorithms to grow market share and deliver greater value.
Wearable Technologies: The company is focused on innovating wearable technologies and telemonitoring solutions to address unmet patient needs and expand long-term growth potential.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: The company anticipates share repurchase as a priority for capital deployment following the divestiture of Sound United. This is expected to be more accretive at the current share price. Future capital deployment strategies may involve a mix of share buybacks, debt reduction, and tuck-in acquisitions of technologies that enhance in-hospital monitoring capabilities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the guidance update and the factors influencing it?
A:The guidance update reflects an 8% to 11% constant currency growth range for the year. Assumptions for the full year remain unchanged, with strong consumable growth and low single-digit capital sales growth. Foreign exchange benefits are being passed through, and headwinds from the shift in 842 are playing out as expected.
Q:What is the progress on sales force alignment and its impact on adoption of advanced parameters?
A:Feedback on the new sales structure has been positive, with better follow-through in regions. However, it is too early to quantify changes in growth outlook or predict the timing of impacts, which are expected more into 2026.
Q:What is the status of Masimo's relationship with Philips and its revenue growth potential?
A:The Philips agreement remains in place, and the relationship is strong. Discussions are ongoing to continue the partnership. Over the past decade, Masimo's presence in Philips' installed base has significantly increased, and this trend is expected to continue.
Q:What is the impact of tariffs and the mitigation efforts being undertaken?
A:The guidance implies $17 million to $19 million of tariff impact for the year. Mitigation actions have reduced the annualized tariff impact to 200-260 basis points, with further medium-term efforts expected to improve by 100-110 basis points. These measures are ongoing and aim to halve the current impact.
Q:Why is the true incremental metric down, and what is the outlook?
A:The first half of the year saw $155 million in incremental value of new contracts, with a strong pipeline for the second half. The metric's fluctuation is due to the timing of large deals, not sales force changes. A strong back half is expected.
Q:What are the expectations for board shipments in the second half of the year?
A:Board shipments are expected to remain in the $60,000 to $65,000 range per quarter, consistent with the first half. Variations depend on OEM ordering patterns, which are seasonal.
Q:When will the impact of new initiatives and products be seen?
A:Details on the timing of new products and initiatives will be provided at the investor conference in December. Clear expectations for next year will be shared then.
Q:What is the progress on the new hemodynamic monitoring technology?
A:Pilots using the LiDCO technology are ongoing, with a full product launch of a next-gen route monitor expected in the back half of next year. The new monitor will feature improved technology and screens.
Q:What is the impact of the recent cyber attack?
A:Operations are fully restored with no material impact on the quarter or full year. Systems have been fortified to prevent future attacks, and the recovery was within the context of insurance coverage.
Q:Are there any changes in competitive dynamics or pressures from generics and reprocessing?
A:Masimo has not experienced significant pressure from generics or reprocessed sensors, unlike its main competitor.
Q:How are product lines outside of pulse-ox performing?
A:Advanced parameters like Rainbow, capnography, and brain monitoring are tracking well and in line with long-range growth targets.
Q:What is the expected seasonality for the third quarter and the impact of currency on guidance?
A:Normal seasonality is expected, with revenues stepping down in Q3 and a strong Q4. Currency benefits have added $5 million to the revenue guidance, with no material impact on EPS.
Q:What is the tax rate assumption for the year?
A:The assumed tax rate for the year is approximately 23.8% at the midpoint of the guidance range.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or quantifiable impacts for the sales force alignment and advanced parameter adoption, stating it was too early to determine. Similarly, they deferred detailed guidance on the timing of new initiatives and products until the investor conference in December. Additionally, while they mentioned fortifying systems post-cyber attack, no specific measures or costs were disclosed.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Asia Pacific
Chief Commercial
Chief Marketing
Commercial Officer
Executive Vice
Japan Asia
LLC Research
Marketing Officer
Officer leader
Research Division
Sound United
Technology Officer
algorithm
commitment
excellence
health
industry
organization
position
region
role
sale force
sale marketing
solution
specialty
strategy
tariff
team
track record
use
wave
world
year experience
MASI Transcript
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Masimo Corporation (MASI) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals positive sentiment with strong financial metrics, optimistic guidance, and strategic growth initiatives. The company projects significant revenue and EPS growth, improved operating margins, and successful tariff impact mitigation. The Q&A session highlights opportunities in Philips' installed base and confidence in revenue objectives. Despite some uncertainties, the focus on advanced monitoring, wearables, and AI integration indicates a positive outlook. The overall sentiment suggests a positive stock price reaction over the next two weeks.
Masimo Corporation (MASI) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-4
Masimo Corporation (MASI) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presented a mixed picture: strong EPS growth and improved margins were overshadowed by unchanged revenue guidance and tariff impacts. Positive feedback on sales restructuring and strong partnerships were tempered by management's vague responses on future initiatives. The Q&A highlighted uncertainties about the timing of new products and sales impacts. The stock price is likely to remain stable due to these mixed signals, with no clear catalyst for significant movement in either direction.
MASI Slides
MASI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
